pharmaphorum15d
FDA won't back Lilly's PD-1 antibody based on Chinese data alone
Lilly licenses sintilimab from Suzhou-based biotech Innovent Biologics ... and Dr Jill Biden. Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being ...
GlobalData on MSN4mon
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
The Suzhou, China-based biotech has presented ... which showed mazdutide to be superior to Eli Lilly’s Trulicity (dulaglutide ...